{"id":"W4407393534","doi":"10.1016/j.annonc.2025.01.009","title":"VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis; Pfizer","keywords":"Medicine; Metastatic breast cancer; Chemotherapy; Oncology; Breast cancer; Internal medicine; Hormone receptor; Cancer; HER2 negative; Mammary gland","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008810888,0.0007514503,0.0008690241,0.0002543071,0.0001541961,0.000748835,0.0004715095,0.0005435279,0.00479321],"category_scores_gemma":[0.0006707851,0.0001829729,0.0008660792,0.0002731929,0.0004632282,0.000574695,0.0002663788,0.001807513,0.0005198214],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008917702,"about_ca_system_score_gemma":0.0005670886,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001171859,"about_ca_topic_score_gemma":0.004288051,"domain_scores_codex":[0.9998037,0.00009696826,0.000008284145,0.00003246001,0.00001552224,0.00004302308],"domain_scores_gemma":[0.9997334,0.00007451219,0.0000508178,0.00001575997,0.000008005332,0.0001176284],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7416816,0.007765173,0.005051314,0.001308195,0.002081734,0.0001480312,0.0001664813,0.006618266,0.01407956,0.001078746,0.008414943,0.2116059],"study_design_scores_gemma":[0.5533536,0.3670108,0.04244354,0.0005167376,0.003863216,0.0008100958,0.0002966251,0.007879296,0.007337203,0.001957319,0.01444658,0.00008493169],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882236,0.006021924,0.0001912647,0.000617768,0.0001992964,0.0001852898,0.001155839,0.0000581426,0.003346822],"genre_scores_gemma":[0.989677,0.00347269,0.0004140253,0.000730828,0.000119342,0.0001704859,0.002162988,0.00002181612,0.003230813],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00479321,"threshold_uncertainty_score":0.01603484,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0593424706167068,"score_gpt":0.3971762921024471,"score_spread":0.3378338214857404,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}